解析度 Pembrolizumab 相关的类固醇难治性苔藓样皮炎与环孢素。
Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
机构信息
School of Medicine, Duke University, Durham, North Carolina, USA
Department of Dermatology, Duke University, Durham, North Carolina, USA.
出版信息
Oncologist. 2019 Mar;24(3):e103-e105. doi: 10.1634/theoncologist.2018-0531. Epub 2019 Jan 7.
Abstract
Checkpoint inhibitors such as pembrolizumab, an anti-PD-1 monoclonal antibody, are a promising new category of oncological therapeutics, associated with a higher risk of immune-related adverse events including dermatological, autoimmune and endocrine sequelae. Here, we present a case of a woman 76 years of age with stage IV lung adenocarcinoma who developed a severe and steroid-refractory lichenoid dermatitis associated with pruritus on pembrolizumab. This eruption resolved completely with a short course of oral cyclosporine. Cyclosporine is a promising and effective treatment option for checkpoint inhibitor-related severe cutaneous eruptions.
摘要
检查点抑制剂，如抗 PD-1 单克隆抗体 pembrolizumab，是一类很有前途的肿瘤治疗新药，与包括皮肤、自身免疫和内分泌后遗症在内的免疫相关不良事件的风险升高相关。在此，我们报告了一例 76 岁女性患者，患有 IV 期肺腺癌，在接受 pembrolizumab 治疗后发生了严重的、类固醇难治性苔藓样皮炎，并伴有瘙痒。该皮疹在短疗程的环孢素治疗后完全消退。环孢素是一种有前途的、有效的治疗选择，可用于治疗检查点抑制剂相关的严重皮肤不良反应。
相似文献
1
Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Oncologist. 2019 Mar;24(3):e103-e105. doi: 10.1634/theoncologist.2018-0531. Epub 2019 Jan 7.
2
Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
Dermatol Online J. 2020 May 15;26(5):13030/qt6348767t.
3
Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab.
BMJ Case Rep. 2023 Jun 20;16(6):e254692. doi: 10.1136/bcr-2023-254692.
4
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
J Cutan Pathol. 2020 Oct;47(10):954-959. doi: 10.1111/cup.13739. Epub 2020 Jun 10.
5
Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
Dermatol Online J. 2019 Sep 15;25(9):13030/qt8sm0j7t7.
6
Annular lichenoid dermatitis.
Clin Exp Dermatol. 2010 Dec;35(8):921-3. doi: 10.1111/j.1365-2230.2010.03836.x.
7
Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001831.
8
Annular Lichenoid Dermatitis of Youth: A Chronic Case Managed Using Pimecrolimus.
Pediatr Dermatol. 2016 Nov;33(6):e360-e361. doi: 10.1111/pde.12987. Epub 2016 Sep 22.
9
Lichen amyloidosus associated with Kimura's disease: successful treatment with cyclosporine.
Dermatology. 2002;204(2):133-5. doi: 10.1159/000051831.
10
PD1 inhibitor induced inverse lichenoid eruption: a case series.
Dermatol Online J. 2020 Dec 15;26(12):13030/qt66b8298z.
引用本文的文献
1
Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib.
Front Oncol. 2025 May 19;15:1495446. doi: 10.3389/fonc.2025.1495446. eCollection 2025.
2
Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.
Liver Int. 2025 Feb;45(2):e16198. doi: 10.1111/liv.16198.
3
Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.
Pharmaceuticals (Basel). 2023 Nov 15;16(11):1610. doi: 10.3390/ph16111610.
4
Steroid-Refractory Lichenoid Eruption Associated with Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
HCA Healthc J Med. 2021 Dec 29;2(6):397-400. doi: 10.36518/2689-0216.1198. eCollection 2021.
5
Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition.
Curr Oncol. 2023 Apr 27;30(5):4527-4537. doi: 10.3390/curroncol30050342.
6
Cutaneous manifestations associated with immune checkpoint inhibitors.
Front Immunol. 2023 Feb 20;14:1071983. doi: 10.3389/fimmu.2023.1071983. eCollection 2023.
7
Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota.
Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2200348119. doi: 10.1073/pnas.2200348119. Epub 2022 Jun 21.
8
"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.
Hum Vaccin Immunother. 2022 May 31;18(3):1889449. doi: 10.1080/21645515.2021.1889449. Epub 2021 Mar 24.
9
Moving towards personalized treatments of immune-related adverse events.
Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3.
本文引用的文献
1
Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
Am J Case Rep. 2018 Mar 27;19:360-364. doi: 10.12659/ajcr.908570.
2
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.
BMJ. 2018 Mar 14;360:k793. doi: 10.1136/bmj.k793.
3
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Am J Clin Dermatol. 2018 Jun;19(3):363-375. doi: 10.1007/s40257-017-0337-2.
4
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
J Am Acad Dermatol. 2017 Nov;77(5):845-854.e5. doi: 10.1016/j.jaad.2017.07.013. Epub 2017 Sep 8.
5
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
6
Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
Am J Dermatopathol. 2017 Jan;39(1):23-27. doi: 10.1097/DAD.0000000000000587.
7
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
Oncologist. 2017 Jan;22(1):70-80. doi: 10.1634/theoncologist.2016-0164. Epub 2016 Aug 17.
8
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. doi: 10.1001/jamadermatol.2016.2226.
9
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12.
10
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
J Invest Dermatol. 2003 Feb;120(2):211-6. doi: 10.1046/j.1523-1747.2003.12040.x.
Zotero 插件